Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-small Cell Lung Cancer Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT06108479
What this trial is testing

Study of DF6215 in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultSolid Tumor Cancer
Dragonfly Therapeutics 35
Early research (Phase 1)Looking for participantsNCT07006727
What this trial is testing

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Who this might be right for
Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate Cancer+8 more
Novartis Pharmaceuticals 116
Early research (Phase 1)Study completedNCT00635596
What this trial is testing

Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer

Who this might be right for
Solid Tumors
Amgen Research (Munich) GmbH 65
Testing effectiveness (Phase 2)WithdrawnNCT04460729
What this trial is testing

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Who this might be right for
Non-small Cell Lung Carcinoma (NSCLC)
Novartis Pharmaceuticals
Early research (Phase 1)Looking for participantsNCT07261631
What this trial is testing

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-Small Cell Lung CancerHR+/HER2- Ductal and Lobular Breast Cancer+3 more
Novartis Pharmaceuticals 180
Testing effectiveness (Phase 2)Looking for participantsNCT05456256
What this trial is testing

LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

Who this might be right for
Adenocarcinoma of LungCarcinoma, Non-Small-Cell Lung
Lantern Pharma Inc. 90
Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)Study completedNCT03085914
What this trial is testing

Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Who this might be right for
Solid Tumor
Incyte Corporation 70
Post-approval studies (Phase 4)Study completedNCT04078152
What this trial is testing

Durvalumab Long-Term Safety and Efficacy Study

Who this might be right for
Solid Tumor
AstraZeneca 163
Not applicableLooking for participantsNCT07633626
What this trial is testing

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Who this might be right for
Advanced ALK/ROS1-positive NSCLCCarcinoma, Non-Small-Cell Lung (NSCLC)Lung Adenocarcinoma+3 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo 24
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Testing effectiveness (Phase 2)Study completedNCT00445848
What this trial is testing

S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
SWOG Cancer Research Network 89
Testing effectiveness (Phase 2)Study completedNCT00970684
What this trial is testing

Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Nathan Pennell, MD, PhD 13
Testing effectiveness (Phase 2)Ended earlyNCT00281827
What this trial is testing

Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Masonic Cancer Center, University of Minnesota 22
Testing effectiveness (Phase 2)Study completedNCT02718066
What this trial is testing

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Who this might be right for
MelanomaRenal Cell CarcinomaNon-Small Cell Lung Cancer
HUYABIO International, LLC. 96
Early research (Phase 1)Study completedNCT00006981
What this trial is testing

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Who this might be right for
Cervical CancerFallopian Tube CancerHead and Neck Cancer+5 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00103116
What this trial is testing

Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Edward Hirschowitz 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT03836352
What this trial is testing

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Who this might be right for
Ovarian CancerHepatocellular CarcinomaNon-small Cell Lung Cancer+2 more
ImmunoVaccine Technologies, Inc. (IMV Inc.) 184
Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Not applicableNo Longer AvailableNCT02784158
What this trial is testing

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerLung CancerAdvanced Malignancies+1 more
Ariad Pharmaceuticals
Next Page